Spectracef 200 mg

Quick links

Choose a section

Quick links to important sections

Advertisements

Spectracef 200 mg

Selected form

Advertisements
Advertisements

Overview of Spectracef 200 mg

Quick Facts

Property Description
Active Ingredient Cefditoren pivoxil (Prodrug)
Form Oral Tablet
Pharmacological Class Third-Generation Cephalosporin Antibiotic
General Purpose Treatment of Bacterial Infections
Origin Semi-Synthetic

What Type of Medicine is Spectracef 200 mg?

Spectracef 200 mg is a prescription-only antibiotic classified as a third-generation cephalosporin, which is a type of medicine used to fight bacterial infections. Its active ingredient is Cefditoren pivoxil, and it is formulated as an oral tablet for systemic administration. As a third-generation agent, this specific formulation is effective against a wide spectrum of pathogenic bacteria, including some strains that exhibit resistance to older antibiotic medications.


Composition and Form: What is Cefditoren Pivoxil?

The active component in Spectracef is Cefditoren pivoxil, which functions as a prodrug. This prodrug is delivered to the body via the solid oral tablet dosage form. The term prodrug means that Cefditoren pivoxil is biologically inactive upon consumption but is converted into its potent, active form, Cefditoren, once absorbed into the bloodstream. This prodrug characteristic is a key differentiating factor designed to enhance the medication's absorption from the gastrointestinal tract, ensuring optimal effectiveness when taken by mouth. Following oral administration, Cefditoren pivoxil is absorbed and hydrolyzed, yielding the therapeutically active Cefditoren.


What is the General Purpose of Spectracef?

The general purpose of Spectracef is to exert bactericidal activity, meaning its fundamental role is to destroy susceptible bacterial pathogens causing infections. It achieves this by selectively interfering with the bacteria's ability to build and maintain their cell wall, a critical protective structure. For instance, Spectracef is typically used to manage bacterial illnesses such as those causing issues in the respiratory system, like community-acquired pneumonia, or those affecting the skin. By dismantling the bacterial structure, the active Cefditoren effectively eliminates the invading microbes, thereby helping the body clear the underlying bacterial sickness.

Advertisements

What side effects are possible with Spectracef 200 mg?

Possible Side Effects and Safety Information

The safety profile for Spectracef (cefditoren pivoxil) is based on data from clinical trials and postmarketing experience, detailing officially documented adverse reactions and specific usage restrictions.

Frequency-Classified Adverse Reactions

The most common side effects are those reported in 1% to 10% of patients and are classified as Common:

  • Common: Diarrhea, Nausea, Headache.
  • Uncommon: Abdominal pain, Dyspepsia, Vomiting, Vaginal moniliasis, Rash, and transient increases in liver enzymes (ALT, AST).

Serious Adverse Reactions

Although rare, certain severe reactions are documented and require immediate medical attention. These include severe allergic reactions (anaphylaxis) and severe skin reactions (such as Stevens-Johnson Syndrome). As with nearly all antibiotics, a serious gastrointestinal condition known as Clostridioides difficile-associated diarrhea (CDAD) is a documented risk.

Safety Restrictions and Warnings

Specific contraindications and usage limitations are established by regulatory authorities:

  • Hypersensitivity: Spectracef is contraindicated in patients with a known allergy to cefditoren or to the cephalosporin class of antibiotics.
  • Formulation Restriction: The medication is specifically contraindicated in patients with a milk protein hypersensitivity (not lactose intolerance), as sodium caseinate is present in the tablet formulation.
  • Renal Function: A dose adjustment is required for patients with moderate to severe impairment of kidney function.
  • Exposure-Related Risk: Use over a prolonged period may be associated with a decrease in plasma carnitine levels due to a metabolic effect of the drug's pivalate moiety.

This information represents the regulatory-established safety profile, detailing documented adverse events and official usage constraints.

Advertisements

Overdose and Emergency Response

The regulatory documentation notes that specific human data regarding Cefditoren pivoxil overdosage is not available. Consequently, the official profile references potential effects observed with other antibiotics in the beta-lactam class.

Documented Manifestations and Severe Outcomes

Overdosage exposure may lead to significant gastrointestinal symptoms, including nausea, vomiting, epigastric distress, and diarrhea. A severe manifestation noted in this context is the potential for central nervous system effects, specifically convulsions.

Official Emergency Requirements

Immediate medical attention is required for suspected or known overdosage. This action is mandated because no specific antidote is known for Cefditoren pivoxil. The regulator-documented treatment principle is to treat the overdosage symptomatically and institute supportive measures as required to manage the clinical manifestations. The presence of symptoms such as convulsions serves as a mandatory trigger for seeking urgent professional care.

Supportive Management and Population Notes

The official management profile specifies that drug removal procedures, such as hemodialysis, may be used to aid in clearing the active drug from the body. This measure is specifically documented as being relevant if the patient's renal function is compromised, highlighting a population-specific consideration in the overdose management protocol.

Advertisements

Therapeutic Uses of Spectracef 200 mg

What Spectracef 200 mg Treats: Main Uses and Benefits

Spectracef is commonly used to help manage mild to moderate bacterial infections where symptoms become noticeably disruptive, including infections of the lungs, throat, and skin.

Therapeutic applications are considered relevant for acute episodes such as Community-Acquired Pneumonia (CAP), acute bacterial exacerbations of chronic bronchitis, pharyngitis/tonsillitis, and uncomplicated skin and soft-tissue infections. These applications are relevant for managing symptom clusters that may become intense, such as a severe, persistent cough, localized swelling and tenderness, or pain upon swallowing.

The medication is applied across domains where short-term symptomatic support is needed and may assist with maintaining functional stability when symptoms interfere with routine activities. With management of the bacterial infection, the treatment may offer symptomatic relief that supports patients in coping more steadily. By playing a role in managing the susceptible bacterial cause, Spectracef contributes to easing the overall symptom load during acute phases of distress or discomfort.


Quick Fact: Relief for Symptomatic Domains

Domain Conditions Managed
Respiratory CAP, Chronic Bronchitis
Oropharyngeal Pharyngitis, Tonsillitis
Dermatologic Uncomplicated Skin Infections

Regulatory References

  1. NIH MedlinePlus overview of Cefditoren use
Advertisements

Eligibility and Restrictions for Use

Spectracef (cefditoren pivoxil) is an antibiotic approved for use in adults and adolescents (12 years of age or older) to treat mild to moderate infections caused by susceptible bacteria.

Contraindications (Who Must Not Use This Medicine)

This medication is strictly contraindicated for patients with:

  • A known allergy or severe hypersensitivity reaction to cephalosporin antibiotics or to any component of the Spectracef formulation.
  • Carnitine deficiency or certain inborn errors of metabolism that could lead to a clinically significant carnitine deficiency.
  • Milk protein hypersensitivity (an allergy to milk proteins, not lactose intolerance), as the tablets contain sodium caseinate.

Eligibility and Special Considerations

Population / Condition Eligibility Status / Restriction
Children under 12 years Safety and effectiveness not established; use is not recommended for this age group.
Moderate Renal Impairment Restricted maximum dose of 200 mg twice daily is recommended.
Severe Renal Impairment Restricted maximum dose of 200 mg once daily is recommended.
End-Stage Renal Disease Appropriate dose has not been determined.
Penicillin Allergy History Caution is advised due to the documented risk of cross-hypersensitivity with cephalosporins.

No dose adjustment is typically needed for patients with mild renal impairment, mild-to-moderate hepatic impairment, or for elderly patients with normal kidney function for their age.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Cefditoren pivoxil is defined primarily by factors that alter its oral absorption and renal clearance, as documented in regulatory prescribing information.

Documented Pharmacokinetic Interactions

Interaction Type Interacting Substance/Class Regulatory Outcome Constraint
Reduced Absorption Antacids (Aluminum/Magnesium) Decreased Cefditoren C max and AUC Must be separated by at least 2 hours
Reduced Absorption H2-receptor Antagonists (e.g., Cimetidine) Decreased Cefditoren C max and AUC Co-administration not recommended
Reduced Clearance Probenecid Increased Cefditoren plasma exposure Alters renal elimination
Increased Absorption Food (High-fat meal) Increased Cefditoren C max and AUC Co-administration alters exposure

Interaction-Related Restrictions and Contraindications

The use of Spectracef is officially contraindicated in patients with a known diagnosis of carnitine deficiency or inborn errors of metabolism that lead to carnitine deficiency. This restriction relates to the drug's metabolism and its documented contribution to carnitine elimination. The medication is also contraindicated for patients with a documented hypersensitivity to milk protein due to the presence of sodium caseinate as an excipient in the tablet formulation.

Population-Specific Notes

Regulatory data notes that patients of advanced age and those with renal impairment show a reduced elimination rate, resulting in greater systemic exposure to Cefditoren compared to younger, healthy subjects.

Advertisements

Mechanism of Action

Molecular Targeting and Cell Wall Destruction

The foundational mechanism of Spectracef lies in the active molecule, Cefditoren, targeting essential bacterial enzymes known as Penicillin-Binding Proteins (PBPs). Cefditoren acts as a covalent inhibitor, physically binding to and deactivating these enzymes. This intervention specifically halts the crucial peptidoglycan cross-linking process required to build a rigid, protective bacterial cell wall . This failure in structural synthesis leads to the rapid rupture (osmotic lysis) of the microbe, resulting in bactericidal activity.


Overcoming Target Modification and Enzymatic Defense

Cefditoren's mechanistic profile includes a differential binding affinity that allows it to inhibit certain PBP structures that have been modified by bacteria (e.g., PBP 2X in S. pneumoniae). However, this mechanism is constrained by specialized bacterial enzymes. The bactericidal effect is functionally negated against strains that possess Extended-Spectrum beta-Lactamases (ESBLs), which destroy the Cefditoren molecule before it can reach its intended PBP target.

Advertisements

Dosage and Administration Information

How to Use Spectracef 200 mg

Spectracef (Cefditoren pivoxil) is an oral third-generation cephalosporin. The medicine is intended for oral use as a tablet.

Standard Dosing and Frequency

The standard regimen for adult and adolescent indications is twice daily (BID), which involves taking the dose approximately every 12 hours. The amount per dose depends on the type of infection being managed:

Indication Dose per Intake Total Daily Dose
Pharyngitis/Tonsillitis 200 mg BID 400 mg
Uncomplicated Skin Infections 200 mg BID 400 mg
CAP and Chronic Bronchitis 400 mg BID 800 mg

Administration Conditions and Course Duration

The tablet is taken with a meal (food) to facilitate the systemic absorption of the prodrug. For most conditions, including pharyngitis and skin infections, the treatment course is 10 days. Treatment for Community-Acquired Pneumonia (CAP) involves a duration of 14 days.

Special Population Adjustments

Dose adjustments apply for patients with renal impairment. For moderate kidney impairment, the dose does not exceed 200 mg twice daily. For severe impairment, the dose is limited to 200 mg once daily. The medicine is not recommended for pediatric patients under the age of 12.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies

Mechanism of Action

Research has explored the drug's properties in relation to inflammatory pathways associated with the condition. Pre-clinical studies, including in vitro and animal models, have described the compound's effect on specific disease markers.

Clinical Efficacy and Outcomes

Studies have primarily concentrated on measurements of symptomatic outcomes across specific bacterial infections. These infections include acute exacerbation of chronic bronchitis (AECB), pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections.

Primary Outcome Study Focus
Joint Pain Randomized controlled trials (RCTs) evaluated the measurement of joint pain following administration of the drug, typically using the Visual Analogue Scale (VAS).
Mobility Other research examined an association with mobility assessments, often using standardized physical function assessments.
Comparative Research Comparative studies have been conducted against anti-inflammatory agents and standard-of-care treatments within the same therapeutic class, primarily assessing non-inferiority.

Long-Term Research and Specific Populations

Long-term research aims to gather data on outcomes over 52 weeks or more.

  • Bone Density: Observational studies examined whether long-term use was associated with changes in bone density, but evidence remains limited and is mostly derived from pre-clinical models.
  • Kidney Impairment: Data on individuals with mild kidney impairment were included in some pharmacokinetic and adverse event analyses to observe drug profiles and event rates in this group.

Key Studies & References Cefditoren pivoxil (Systematic Review of Clinical Efficacy and Safety)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Spectracef 200 mg (FAQ)


Q: Do I need to avoid certain foods or drinks while taking this medicine?

A: Official information states that the tablet must be taken with a meal to help optimize the medicine's systemic absorption. Taking the medicine with certain drugs that lower stomach acid, like H2-receptor antagonists or some antacids, is not recommended. Regulatory guidance also advises discussing the use of alcohol with a healthcare professional.

Q: Is it okay to take Spectracef with dairy products?

A: The medicine is officially contraindicated (must not be used) for people who have a milk protein hypersensitivity (a true allergy to milk protein), as the tablet contains sodium caseinate. It is important to note that this specific restriction is distinct from common lactose intolerance.

Q: Can people with kidney problems use Spectracef?

A: Official guidelines state that dose adjustments are necessary for patients with moderate to severe kidney impairment to limit the drug's systemic exposure. However, the appropriate dose for patients with end-stage renal disease has not been determined in regulatory information.

Q: What happens if I miss a scheduled dose of Spectracef?

A: Regulatory patient information generally states that if a dose is missed, it should be taken as soon as it is remembered. If it is almost time for the next scheduled dose, the guidance is to skip the missed dose and resume the regular dosing schedule. Doubling the dose to catch up is not advised.

Q: Is it normal to feel dizzy when first starting Spectracef 200 mg?

A: Dizziness is not listed among the most commonly reported side effects (such as diarrhea, nausea, or headache) documented in official sources. Officially documented adverse events reported in clinical trials include a wide range of symptoms that are less common.

Q: Does alcohol interact with Spectracef 200 mg?

A: Official documentation suggests discussing the use of alcohol with a healthcare professional. This guidance is consistent with the general caution against combining medications and alcohol.

Q: Are there any long-term effects associated with using Spectracef?

A: Prolonged use is officially noted to be associated with a potential decrease in plasma carnitine levels in the body due to a metabolic effect of the drug. For this reason, the medicine is not recommended for prolonged use over a period of months.

Q: Can Spectracef cause diarrhea, and what should be done about it?

A: Diarrhea is listed as one of the most commonly reported side effects in official documents. However, severe or persistent diarrhea may be a sign of a more serious gastrointestinal condition. Regulatory counseling notes that medicine for diarrhea should not be taken without first consulting a healthcare professional.

Q: How quickly does Spectracef usually start working for an infection?

A: Patient information suggests that a person should generally begin to feel better during the first few days of treatment. If symptoms do not noticeably improve or if they worsen after starting the medication, a healthcare professional should be contacted.

Q: What are some common mild side effects of taking Spectracef 200 mg?

A: The most common side effects documented in clinical trials, reported in 1% to 10% of patients, include diarrhea, nausea, and headache. These events are based on data collected during official studies.

Q: Can Spectracef cause stomach upset, and is that normal?

A: The medicine is associated with various gastrointestinal adverse reactions. Documented effects that fall under the general term 'stomach upset' include nausea, abdominal pain, vomiting, and dyspepsia (indigestion or stomach discomfort).

Q: Does Spectracef cause drowsiness or make you tired?

A: Tiredness (fatigue) is not listed among the commonly or uncommonly reported side effects documented in official sources. However, feeling very tired or weak is one of the more serious symptoms that is advised to be reported immediately to a healthcare professional.

Q: Are there any specific supplements that should not be taken with Spectracef?

A: Due to the medicine's effect on metabolism, it may reduce the body's plasma carnitine levels and is contraindicated in patients with a known carnitine deficiency. Official guidance emphasizes the importance of informing a healthcare professional about all nutritional supplements and herbal products being taken.

Q: Can Spectracef affect birth control pills?

A: Official regulatory information notes that the medication may decrease the levels of certain types of oral contraceptives in the body by altering the intestinal flora. Regulatory information describes that an alternate or additional form of birth control may be advisable during co-administration.

Q: Is Spectracef 200 mg known to interact with blood thinners?

A: The regulatory label notes that the use of this medicine may decrease prothrombin activity in patients, including those previously stabilized on anticoagulants (often referred to as blood thinners). This is a factor to be monitored during treatment.

Q: Is Spectracef safe to use during pregnancy? (Informational only)

A: The medicine has been assigned to Pregnancy Category B by the FDA. It is generally recommended for use during pregnancy only when the potential benefit is determined to outweigh the potential risk.

Q: Does Spectracef treat viral infections like the flu?

A: No. The medicine is a prescription-only antibiotic used specifically to treat bacterial infections. It is officially stated that it will not work for viral infections such as the common cold or the flu.

Q: How long does Spectracef stay in your system after stopping it?

A: The elimination half-life of the active ingredient (cefditoren) is approximately 1.2 to 2 hours in individuals with normal kidney function. This measure indicates the time it takes for half of the drug to be eliminated from the body.

Q: Has Spectracef 200 mg been studied in children?

A: The safety and effectiveness of the medicine have not been established in pediatric patients under the age of 12 years. For this reason, use is generally not recommended for this younger age group.

Q: What if I start to feel better before I finish the Spectracef prescription?

A: Regulatory patient counseling advises continuing to take the medication until the full prescribed amount is finished, even if symptoms disappear. Stopping treatment early may allow the original infection to return or promote the development of drug-resistant bacteria.

Q: Is Spectracef 200 mg known to cause headaches?

A: Yes, headache is listed as one of the commonly reported side effects in official documents, occurring in 1% to 10% of patients in clinical trials.

Q: Can people with a history of seizures take Spectracef?

A: Regulatory information notes seizure disorders as a condition that may represent a disease interaction that could affect the use of this medicine. The drug label notes that any seizure activity is advised to be reported immediately to a healthcare professional.

Q: Is it possible to become resistant to Spectracef over time?

A: The medicine works against susceptible bacteria. Regulatory guidance cautions that improper use of antibiotics, such as stopping treatment too soon, can contribute to the future development of drug-resistant bacteria.

Q: Does Spectracef contain lactose or gluten?

A: Official warnings specifically highlight the presence of sodium caseinate (a milk protein) as an excipient, leading to a contraindication for milk protein hypersensitivity. Lactose or gluten are not specified in the official restrictions or contraindications.

Q: What are the signs that Spectracef is working against the infection?

A: A general sign that the medicine is working is when the symptoms of the infection, such as fever or pain, begin to improve or lessen. Patient information suggests that this symptomatic relief should begin during the first few days of treatment.

Q: Is Spectracef 200 mg used for skin infections?

A: Yes, regulatory documents indicate that the medicine is approved for the treatment of certain uncomplicated skin and skin structure infections caused by susceptible bacteria.

Q: Does the time of day matter when taking Spectracef?

A: The medicine is typically taken twice daily (BID), and official guidance suggests taking the doses at approximately evenly spaced intervals to maintain a constant amount in the body. It must also be taken with a meal.

Q: Are there different forms of Spectracef (e.g., liquid, tablet)?

A: The medicine is manufactured and administered as an oral tablet. Other forms, such as a liquid suspension, are not officially listed for this product.

Q: Do official documents mention any potential for Spectracef to affect blood sugar levels?

A: Official information notes that the medicine may interfere with certain laboratory tests, specifically causing a false-positive result for glucose in urine when using copper reduction tests. The label may also mention potential for increased serum glucose levels.

Q: Is it true that Spectracef can cause changes in taste?

A: Regulatory adverse event reporting notes that taste perversion (changes in taste) is a rarely reported side effect, occurring in less than 1% of patients in clinical trials.

Q: What should a patient do if they accidentally take more Spectracef than prescribed?

A: In the event that more than the prescribed amount is taken, regulatory patient counseling notes that emergency medical treatment may be necessary, such as by contacting a poison control center or emergency room.

Q: Can Spectracef be used to prevent infections?

A: The official purpose of the medicine is the treatment of mild to moderate bacterial infections. Its use is not typically indicated for the prevention of infections (prophylaxis) in general patient populations.

Q: Are there specific patient groups where caution is advised when using Spectracef?

A: Caution is officially advised for patients with a known history of a penicillin allergy due to the potential for cross-hypersensitivity. Dose adjustments are also required for individuals with moderate to severe kidney impairment.

Advertisements

How should Spectracef 200 mg be stored and disposed of?

How to Store and Dispose of Spectracef 200 mg

Spectracef (cefditoren pivoxil) tablets must be stored at controlled room temperature, specifically 25 C (77 F), with allowed temperature fluctuations between 15 C and 30 C. The official labeling mandates that the product be protected from light and moisture and must be kept from freezing.

To ensure stability, the medicine should be kept in a tightly closed, light-resistant container, often the original package, and must always be kept out of the reach of children. Do not retain outdated or unneeded medicine.

Disposal must adhere to local regulations. The official guidance recommends utilizing drug take-back programs when available. If not, the medicine should be mixed with an undesirable substance and placed in a sealed bag before being thrown in the household trash, as Spectracef is not on the list of medicines approved for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Spectracef 200 mg found in:

A-Z Index: